Colorectal Cancer: Update Bulletin #2 [March 2018]
Gain new key opinion leader (KOL) insights on the latest events happening in the CRC treatment landscape
Topics covered include expert opinions on; the potential of MabVax Therapeutics’ human antibody-based radioimmunotherapy product, MVT-1075; views on the new clinical data presented at the ASCO 2018 Gastrointestinal Cancers Symposium for Taiho Oncology’s Lonsurf (trifluridine and tipiracil); views on new data announced from the Phase II CheckMate-142 trial evaluating Opdivo (nivolumab; Merck & Co.) and Yervoy (ipilimumab; BMS) for the treatment of patients with DNA mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) mCRC.
Business Questions:
Topics covered include expert opinions on; the potential of MabVax Therapeutics’ human antibody-based radioimmunotherapy product, MVT-1075; views on the new clinical data presented at the ASCO 2018 Gastrointestinal Cancers Symposium for Taiho Oncology’s Lonsurf (trifluridine and tipiracil); views on new data announced from the Phase II CheckMate-142 trial evaluating Opdivo (nivolumab; Merck & Co.) and Yervoy (ipilimumab; BMS) for the treatment of patients with DNA mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) mCRC.
Business Questions:
- How do KOLs perceive MVT-1075’s mechanism of action?
- What are the experts’ views on targeting CA19-9 positive malignancies?
- What concerns, if any, do KOLs have regarding MVT-1075?
- How do KOLs view the NLR marker’s potential role in guiding clinical decisions related to Lonsurf?
- What are the KOLs’ views on the Lonsurf safety and tolerability data in elderly patients?
- How do KOLs perceive the potential of Lonsurf and oxaliplatin in combination?
- What are the KOLs’ views on the new data presented from the CheckMate-142 trial?
- Where in the treatment paradigm do KOLs believe the nivolumab plus ipilimumab combination should be used?
- What concerns do KOLs raise about using nivolumab and ipilimumab in combination?
